Current Report Filing (8-k)
December 12 2016 - 6:04AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 9, 2016
Atossa Genetics Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or jurisdiction of incorporation
or organization)
001-35610
(Commission File Number)
26-4753208
(I.R.S. Employer Identification Number)
107 Spring Street, Seattle, WA 98104
(Address of principal executive offices
(Zip Code)
Registrant's telephone number: (206) 325-6086
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act
|
(17CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act
|
(17CFR 240.13e-4(c))
On December 9, 2016,
from 5 p.m. to 7 p.m., a poster was presented at The San Antonio Breast Cancer Symposium featuring Atossa Genetic Inc.’s
(the “Company”) clinical study titled “OT3-02-08: Open Label, phase 2 safety, efficacy, and pharmacokinetic study
of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or
lumpectomy.” A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated into
this Item 8.01 by this reference.
This Current Report
on Form 8-K contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including statements about the Company’s ongoing Phase 2 clinical study.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. While the
Company believes its plans, intentions and expectations reflected in those forward-looking statements are reasonable, these plans,
intentions or expectations may not be achieved. The Company’s actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the forward-looking statements. For information about the factors that could cause
such differences, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, including
the information discussed under the captions “Item 1 Business,” “Item 1A. Risk Factors” and “Item
7 Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as the Company’s
various other filings with the SEC including reports on Forms 10-Q and 8-K. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statement.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Poster presentation presented December 9, 2016*
_________________
*Filed herewith.
|
Signature(s)
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
ATOSSA GENETICS INC.
/s/ Kyle Guse
|
Date: December 9, 2016
|
|
By: Kyle Guse
Its: General Counsel and Chief Financial Officer
|
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024